SIPA1 Antibody

What is SIPA1 and what cellular functions does it regulate in experimental models?

SIPA1 was initially characterized as a mitogen-inducible gene encoding a GTPase-activating protein for Rap1 and Rap2 . Recent research has revealed its multifunctional nature, with significant roles in:

• Signal transduction pathways

• Cell adhesion and migration mechanisms

• DNA synthesis and transcriptional regulation

• Metastatic progression in cancer models

Notable is SIPA1's dual functionality - it acts both through its canonical role as a Rap-GTPase-activating protein and through a newly discovered function as a transcription factor that directly binds DNA . This transcription factor activity was verified through multiple experimental approaches including EMSA, co-immunoprecipitation, and dual-luciferase reporter assays .

In cancer progression models, SIPA1 has been implicated in regulating barrier function in breast cancer cells, potentially through the ROCK pathway . Additionally, SIPA1 has been shown to enhance malignancy by regulating MYH9 in extracellular vesicles and altering glucose metabolism .

What are the optimal techniques for detecting SIPA1 subcellular localization?

SIPA1 exhibits dynamic subcellular localization that researchers must account for in experimental design. Based on immunofluorescence imaging and Western blotting studies, SIPA1 primarily localizes in the cytoplasm under serum-starved conditions but translocates to the nucleus upon stimulation with fibronectin .

Recommended detection methods:

• Immunofluorescence imaging: Particularly useful for visualizing the time-dependent translocation of SIPA1. Research has shown that after 12 hours of fibronectin (5 μg/mL) stimulation, SIPA1 appears in both cytoplasm and nucleus, with significant nuclear accumulation observed after 24 hours .

• Nuclear/cytoplasmic fractionation with Western blotting: This technique provides quantitative assessment of SIPA1 distribution. When implementing this method, researchers should include appropriate nuclear (e.g., lamin B) and cytoplasmic (e.g., GAPDH) markers as controls .

• Co-immunoprecipitation with nuclear transport proteins: This can reveal the mechanisms of nuclear transport. Studies have identified that SIPA1 interacts with importin β1 and importin 7 during nuclear translocation .

When designing localization experiments, researchers should consider using physiologically relevant stimulation conditions, such as fibronectin exposure, to trigger the nuclear translocation of SIPA1.

How should researchers validate the specificity of SIPA1 antibodies?

Antibody validation is critical for reliable SIPA1 research. Recommended validation strategies include:

• Genetic knockdown controls: Use siRNA or shRNA to reduce SIPA1 expression. The search results describe specific constructs for SIPA1 knockdown:

  • Construct 1: 5'-AGCTTAAAAATACCTTTGAGCCGAGGCCATCTCTTGAATGGCCTCGGCTCAAAGGTAGGG-3'

  • Construct 2: 5'-AGCTTAAAAATGCGGCTGTGTCCGTCCTGTCTCTTGAACAGGACGGACACAGCCGCAGGG-3'

• Western blot analysis: Should show reduced signal intensity in knockdown samples compared to controls.

• Immunoprecipitation: Can confirm specificity by pulling down SIPA1 and identifying the protein by mass spectrometry.

• Recombinant protein controls: Express tagged versions (e.g., HA-tagged SIPA1) to verify antibody recognition .

• Domain-specific antibodies: When studying particular functions, domain-specific antibodies may be required. For transcription factor studies, anti-SIPA1-DBR (DNA binding region) antibodies have been developed and validated .

What methodological approaches should be employed to study SIPA1's transcription factor activity?

Recent discovery of SIPA1 as a transcription factor represents a paradigm shift in understanding its cellular functions. Researchers investigating this aspect should consider the following approaches:

• DNA-binding assays:

  • EMSA (Electrophoretic Mobility Shift Assay): Research has demonstrated that SIPA1 binds directly to DNA segments containing the TGAGTCAB motif. Labeled DNA probes (such as cy7-labeled Ps1) can be used, with specificity confirmed through competition with unlabeled probes .

  • Isothermal Titration Calorimetry (ITC): This technique allows quantitative measurement of binding affinity. Studies have determined the binding constant (Ka) of SIPA1-dN to Ps1 as 2.01E5 ± 1.78E5 M-1 .

• Promoter activity assessment:

  • Dual-luciferase reporter assays: Have confirmed that SIPA1 enhances the transcriptional activity of promoters containing the TGAGTCAB motif. Specific promoters shown to be regulated include EPAS1, ITGB1, MYH9, ITGB4, and TGFBI .

• Domain identification:

  • The DNA-binding region (DBR) has been localized to amino acids 764-864. Researchers can create deletion mutants (ΔDBR) to verify functional significance .

• ChIP-seq analysis:

  • While not explicitly mentioned in the search results, this would be a logical next step to identify genome-wide SIPA1 binding sites.

When designing transcription factor studies, researchers should consider both the canonical GTPase-activating function and the newly identified transcription factor activity to obtain a comprehensive understanding of SIPA1's role.

How can researchers effectively study SIPA1's role in the ROCK pathway and cancer cell migration?

SIPA1 appears to regulate the ROCK pathway, which is critical for cell migration and invasion. For investigating this relationship, researchers should implement these methodological approaches:

• Genetic manipulation studies:

  • SIPA1 knockdown: Studies in MDA-MB-231 breast cancer cells showed that SIPA1 knockdown cells no longer responded to ROCK inhibitor (Y-27632), suggesting a functional relationship .

• Protein expression analysis:

  • Immunohistochemistry (IHC): In vivo studies have shown that SIPA1 knockdown tissues exhibit significantly lower levels of ROCK and phosphorylated ROCK .

• Inhibitor studies:

  • Pathway-specific inhibitors: Testing various inhibitors (ROCK, N-WASP, ARPs, WAVEs, MAPK, ERK, PLC-gamma) can help identify which pathways are specifically affected by SIPA1 .

• Migration and invasion assays:

  • Transwell migration assays: Have demonstrated that SIPA1 knockdown reduces migratory capacity of cancer cells .

  • Wound healing assays: Can complement transwell assays to assess collective cell migration.

• In vivo tumor models:

  • SIPA1 knockdown xenografts: Allow assessment of tumor growth, architecture, and protein expression changes in response to pathway inhibitors .

Key experimental finding: In control tumors, phosphorylated ROCK increased after treatment with ROCK inhibitor (ROCKi), while in SIPA1 knockdown tumors, phosphorylated ROCK decreased after ROCKi treatment (p<0.05) . This paradoxical response suggests a complex regulatory relationship warranting further investigation.

What approaches should be used to investigate the functional domains of SIPA1 protein?

Understanding SIPA1's domain structure is essential for elucidating its diverse functions. Researchers should consider:

• Expression of recombinant domain fragments:

  • Studies have successfully expressed and purified domain-specific fragments:

    • SIPA1-dN (N-terminal deleted SIPA1)

    • SIPA1-PDZ (540-763 aa)

    • SIPA1-C1 (764-1042 aa)

    • SIPA1-DBR (764-864 aa)

• Domain deletion mutants:

  • Deletion of the DNA-binding region (DBR) in SIPA1 has been shown to arrest triple-negative breast cancer migration, invasion, and recurrence .

• Structural modeling:

  • Tertiary structure modeling identified that the 764-864 aa region contains several α-helices and β-sheets, while the 865-1042 aa region lacks explicit stable secondary structures .

• Domain-specific antibodies:

  • Anti-SIPA1-DBR antibodies have been developed and shown to inhibit the interaction between SIPA1-dN and DNA (Cy7-Ps1) .

• Functional rescue experiments:

  • Expressing specific domains in knockdown cells can help determine which domains are necessary and sufficient for particular functions.

How should researchers address contradictory findings about SIPA1's mechanistic actions?

Some studies indicate that SIPA1 may act through both Rap1-dependent and Rap1-independent mechanisms. To reconcile these findings:

• Comprehensive pathway analysis:

  • Zhang et al. demonstrated that Rap1 activity was unaltered when SIPA1 was knocked down in MDA-MB-231 cells, despite significant impairment of cell mobility. This suggests that SIPA1 regulates cancer cell mobility through Rap1-independent pathways .

• Multiple functional readouts:

  • Assess multiple endpoints: Besides migration, measure proliferation, apoptosis, and cell cycle progression. Studies in glioma cells showed that SIPA1 knockdown affected all these parameters .

• Context-dependent analysis:

  • SIPA1's function may vary by cancer type or cellular context. Compare results across multiple cell lines.

• Integrated multi-omics approach:

  • Combine transcriptomics, proteomics, and functional assays to build a comprehensive model of SIPA1's actions.

• Temporal dynamics:

  • Consider that SIPA1 may have different functions depending on its subcellular localization, which changes over time after stimulation .

What are the technical challenges in designing effective qPCR primers for SIPA1 expression analysis?

For reliable quantification of SIPA1 mRNA levels, researchers should consider:

• Validated primer sequences:

  • Sense primer: 5'-CCAGCTGGATACCAAAACGG-3'

  • Anti-sense primer: 5'-CCTCAGGAGCTGTTGCTGGT-3'

• Related gene detection:
  For studies investigating SIPA1-related genes:

  • SIPA1L1 sense: 5'-CGAAGGGTTTGGGGTGAG-3'

  • SIPA1L1 antisense: 5'-ACGTCGGCTCCATCTGGT-3'

  • Rap1ga sense: 5'-CCAAGAACAGAGTGGAGTCG-3'

  • Rap1ga antisense: 5'-TGTGCAGGCCTGTATCATCC-3'

• Normalization strategy:

  • mRNA levels should be normalized to a housekeeping gene such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) .

• Detection system:

  • ABI PRISM 7900HT Sequence Detection System has been successfully used for SIPA1 mRNA quantification .

• RNA quality control:

  • Ensure high-quality RNA extraction before cDNA synthesis to avoid artifacts.

What experimental approaches address the challenge of SIPA1's dual functionality?

SIPA1's dual role as a GTPase-activating protein and transcription factor presents unique experimental challenges:

• Subcellular fractionation:

  • Essential for distinguishing cytoplasmic (GTPase-related) versus nuclear (transcription factor) activities.

• Functional protein domains:

  • For GTPase activity: RapGAP domain

  • For transcription factor activity: DNA-binding region (DBR, 764-864 aa)

• Activity-specific assays:

  • For GTPase activity: Rap1 activation kit (pull-down with RalGDS beads followed by immunoblotting)

  • For transcription factor activity: Dual-luciferase reporter assays with promoter constructs containing the TGAGTCAB motif

• Domain-specific mutants:

  • Create and express constructs lacking specific functional domains to dissect their individual contributions.

How can researchers optimize immunohistochemistry protocols for SIPA1 detection in tissue samples?

Based on published research methodologies:

• Sample preparation:

  • Studies have successfully used both frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples .

• Antigen retrieval:

  • For FFPE samples, heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended.

• Antibody selection:

  • Choose antibodies validated for IHC applications.

  • Consider the specific domain you wish to detect (full-length vs. DNA-binding region).

• Signal amplification:

  • For low-expression tissues, consider using tyramide signal amplification systems.

• Quantification method:

  • Semi-quantitative scoring systems have been used, assessing both staining intensity and percentage of positive cells .

• Controls:

  • Include positive control tissues with known SIPA1 expression.

  • Use SIPA1 knockdown tissues as negative controls.

  • Compare expression with phospho-ROCK levels to assess pathway relationships .

What emerging techniques might enhance our understanding of SIPA1's transcription factor activity?

Based on current methodological gaps and recent advances:

• ChIP-seq analysis:

  • To map genome-wide binding sites and identify comprehensive target gene networks.

• CUT&RUN or CUT&Tag:

  • These techniques offer higher resolution and lower background than traditional ChIP-seq.

• Single-cell transcriptomics:

  • To understand cell-to-cell variation in SIPA1-mediated transcriptional responses.

• HiChIP or ChIA-PET:

  • To explore how SIPA1 binding may influence three-dimensional genome organization.

• CRISPR-based approaches:

  • CRISPR interference or activation at SIPA1 binding sites to functionally validate target genes.

• Structural biology techniques:

  • X-ray crystallography or cryo-EM to determine the three-dimensional structure of SIPA1's DNA-binding domain complexed with target DNA sequences.

How might researchers integrate multiple methodologies to resolve contradictory findings about SIPA1's function?

A comprehensive multi-disciplinary approach could include:

• Parallel analysis across multiple cancer types:

  • Compare SIPA1 function in breast cancer, glioma, and other cancer types to identify context-dependent effects .

• Temporal dynamics analysis:

  • Track SIPA1 localization, binding partners, and target gene expression over time after stimulation.

• Systems biology approach:

  • Integrate transcriptomics, proteomics, and functional data to build comprehensive regulatory networks.

• In vivo validation:

  • Use conditional knockout models to confirm in vitro findings in physiologically relevant contexts.

• Patient-derived xenografts:

  • Test SIPA1 function in models that better recapitulate human tumor heterogeneity.

• Multi-omics single-cell analysis:

  • To understand cellular heterogeneity in SIPA1 response.